Austin Private Wealth LLC Has $430,000 Holdings in Pfizer Inc. (NYSE:PFE)

Austin Private Wealth LLC trimmed its position in Pfizer Inc. (NYSE:PFE) by 3.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 14,859 shares of the biopharmaceutical company’s stock after selling 586 shares during the period. Austin Private Wealth LLC’s holdings in Pfizer were worth $430,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Olistico Wealth LLC acquired a new stake in shares of Pfizer in the second quarter valued at approximately $25,000. MFA Wealth Advisors LLC bought a new stake in Pfizer during the 2nd quarter worth about $29,000. Quarry LP bought a new position in shares of Pfizer in the 2nd quarter valued at about $31,000. Financial Connections Group Inc. acquired a new stake in shares of Pfizer in the second quarter valued at about $34,000. Finally, ESL Trust Services LLC acquired a new position in Pfizer during the first quarter valued at approximately $37,000. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on PFE. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. UBS Group lifted their price objective on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. Eight equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.58.

Insider Activity

In other news, Director Scott Gottlieb bought 1,000 shares of the stock in a transaction on Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Pfizer Price Performance

PFE stock traded down $0.04 during midday trading on Tuesday, reaching $27.72. The company had a trading volume of 5,335,787 shares, compared to its average volume of 37,133,770. The company has a market capitalization of $157.08 billion, a price-to-earnings ratio of 37.51, a price-to-earnings-growth ratio of 0.89 and a beta of 0.67. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54. The stock has a 50 day moving average price of $29.01 and a 200-day moving average price of $28.63.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.40%. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter in the prior year, the firm posted ($0.17) EPS. The firm’s quarterly revenue was up 31.2% on a year-over-year basis. Equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 6.06%. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.